Immune System Disease clinical trials at UCSD

1 in progress, 0 open to eligible people

Diamyd Administered Into Lymph Nodes in Individuals Recently Diagnosed With Type 1 Diabetes, Carrying the HLA DR3-DQ2 Haplotype
Sorry, not currently recruiting here
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
San Diego, California and other locations

Last updated: August 31, 2023

Diamyd Administered Into Lymph Nodes in Individuals Recently Diagnosed With Type 1 Diabetes, Carrying the HLA DR3-DQ2 Haplotype